Copy to clipboard 
Orthofix reported 3Q25 orthopedic sales of $205.6 million, up 4.6% compared to the third quarter of 2024. For the first nine months of the year, the company generated $602.4 million in orthopedic sales, up 3.2% compared to the prior period.
Excluding discontinued M6 sales, the company’s U.S. sales net sales grew 8% and saw a 10% bump in procedural volume. These results, fueled by continued adoption of the 7D FLASH navigation system, included 24% growth in lateral, 17% growth in posterior and cervical as well as 18% growth in MIS lumbar.
Orthofix is banking on market share gains with the 2H26 full launch of its VIRATA Spinal Fixation system that features proprietary pedicle screws and instruments that integrate seamlessly with 7D.
In trauma, the company continued its expansion into the U.S., marking the fifth straight quarter of double-digit growth there. Overall trauma gains were driven by TrueLok Elevate, FITBONE Bone Transport and the FITBONE Trochanteric lengthening nail.
Bone Growth Therapies grew nearly 6% on the strength of cross-selling and access to multiple call points.
Orthofix narrowed its guidance range to $810 million to $814 million with a midpoint of $812 million, excluding M6 contributions.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 3Q25 | 3Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Spine | $71.7 | $70.1 | $1.6 | 2.3% |
| Trauma | $33.6 | $30.5 | $3.1 | 10.1% |
| Orthobiologics | $35.3 | $34.3 | $1.0 | 2.8% |
| Enabling Technology | $3.9 | $3.8 | $0.1 | 2.5% |
| Other (Bone Growth Therapies) | $61.2 | $57.9 | $3.3 | 5.7% |
| Total | $205.6 | $196.6 | $9.0 | 4.6% |
| Segment | 9mo25 | 9mo24 | $ Chg | % Chg |
|---|---|---|---|---|
| Spine | $213.8 | $213.0 | $0.8 | 0.4% |
| Trauma | $96.7 | $88.4 | $8.3 | 9.4% |
| Orthobiologics | $104.8 | $105.1 | ($0.3) | (0.2%) |
| Enabling Technology | $8.3 | $7.9 | $0.4 | 5.5% |
| Other (Bone Growth Therapies) | $178.8 | $169.5 | $9.3 | 5.5% |
| Total | $602.4 | $583.8 | $18.6 | 3.2% |
Orthopedic Sales by Geography
| Region | 3Q25 | 3Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $170.3 | $166.6 | $3.7 | 2.2% |
| OUS | $35.3 | $30.0 | $5.3 | 17.8% |
| EMEA | $14.3 | $13.2 | $1.1 | 8% |
| ROW | $21.0 | $16.7 | $4.3 | 25.5% |
| Total | $205.6 | $196.6 | $9.0 | 4.6% |
| Region | 9mo25 | 9mo24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $503.8 | $493.6 | $10.2 | 2.1% |
| OUS | $98.6 | $90.2 | $8.4 | 9.3% |
| EMEA | $41.4 | $39.3 | $2.2 | 5.5% |
| ROW | $57.2 | $51.0 | $6.2 | 12.2% |
| Total | $602.4 | $583.8 | $18.6 | 3.2% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $205.6 | |
| Cost of Sales | $57.1 | 27.8% |
| General and Admin | $148.1 | 72% |
| R & D | $14.8 | 7.2% |
| Other | $8.4 | 4.1% |
| Net Earnings | ($22.8) | (11.1%) |
Orthofix reported 3Q25 orthopedic sales of $205.6 million, up 4.6% compared to the third quarter of 2024. For the first nine months of the year, the company generated $602.4 million in orthopedic sales, up 3.2% compared to the prior period.
Excluding discontinued M6 sales, the company's U.S. sales net sales grew 8% and saw a 10% bump in...
Orthofix reported 3Q25 orthopedic sales of $205.6 million, up 4.6% compared to the third quarter of 2024. For the first nine months of the year, the company generated $602.4 million in orthopedic sales, up 3.2% compared to the prior period.
Excluding discontinued M6 sales, the company’s U.S. sales net sales grew 8% and saw a 10% bump in procedural volume. These results, fueled by continued adoption of the 7D FLASH navigation system, included 24% growth in lateral, 17% growth in posterior and cervical as well as 18% growth in MIS lumbar.
Orthofix is banking on market share gains with the 2H26 full launch of its VIRATA Spinal Fixation system that features proprietary pedicle screws and instruments that integrate seamlessly with 7D.
In trauma, the company continued its expansion into the U.S., marking the fifth straight quarter of double-digit growth there. Overall trauma gains were driven by TrueLok Elevate, FITBONE Bone Transport and the FITBONE Trochanteric lengthening nail.
Bone Growth Therapies grew nearly 6% on the strength of cross-selling and access to multiple call points.
Orthofix narrowed its guidance range to $810 million to $814 million with a midpoint of $812 million, excluding M6 contributions.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 3Q25 | 3Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Spine | $71.7 | $70.1 | $1.6 | 2.3% |
| Trauma | $33.6 | $30.5 | $3.1 | 10.1% |
| Orthobiologics | $35.3 | $34.3 | $1.0 | 2.8% |
| Enabling Technology | $3.9 | $3.8 | $0.1 | 2.5% |
| Other (Bone Growth Therapies) | $61.2 | $57.9 | $3.3 | 5.7% |
| Total | $205.6 | $196.6 | $9.0 | 4.6% |
| Segment | 9mo25 | 9mo24 | $ Chg | % Chg |
|---|---|---|---|---|
| Spine | $213.8 | $213.0 | $0.8 | 0.4% |
| Trauma | $96.7 | $88.4 | $8.3 | 9.4% |
| Orthobiologics | $104.8 | $105.1 | ($0.3) | (0.2%) |
| Enabling Technology | $8.3 | $7.9 | $0.4 | 5.5% |
| Other (Bone Growth Therapies) | $178.8 | $169.5 | $9.3 | 5.5% |
| Total | $602.4 | $583.8 | $18.6 | 3.2% |
Orthopedic Sales by Geography
| Region | 3Q25 | 3Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $170.3 | $166.6 | $3.7 | 2.2% |
| OUS | $35.3 | $30.0 | $5.3 | 17.8% |
| EMEA | $14.3 | $13.2 | $1.1 | 8% |
| ROW | $21.0 | $16.7 | $4.3 | 25.5% |
| Total | $205.6 | $196.6 | $9.0 | 4.6% |
| Region | 9mo25 | 9mo24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $503.8 | $493.6 | $10.2 | 2.1% |
| OUS | $98.6 | $90.2 | $8.4 | 9.3% |
| EMEA | $41.4 | $39.3 | $2.2 | 5.5% |
| ROW | $57.2 | $51.0 | $6.2 | 12.2% |
| Total | $602.4 | $583.8 | $18.6 | 3.2% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $205.6 | |
| Cost of Sales | $57.1 | 27.8% |
| General and Admin | $148.1 | 72% |
| R & D | $14.8 | 7.2% |
| Other | $8.4 | 4.1% |
| Net Earnings | ($22.8) | (11.1%) |
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
